-
1
-
-
69749117558
-
ENETS consensus guidelines for standards of care in neuroendocrine tumors: Chemotherapy in patients with neuroendocrine tumors
-
Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, et al. ENETS Consensus Guidelines for Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009;90:214-9.
-
(2009)
Neuroendocrinology
, vol.90
, pp. 214-219
-
-
Eriksson, B.1
Annibale, B.2
Bajetta, E.3
Mitry, E.4
Pavel, M.5
Platania, M.6
-
2
-
-
0018866070
-
Somatostatin inhibits diarrhea in the carcinoid syndrome
-
Dharmsathaphorn K, Sherwin RS, Cataland S, Jaffe B, Dobbins J. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980;92:68-9. (Pubitemid 10182168)
-
(1980)
Annals of Internal Medicine
, vol.92
, Issue.1
, pp. 68-69
-
-
Dharmsathaphorn, K.1
Sherwin, R.S.2
Cataland, S.3
-
3
-
-
0024573688
-
Use of somatostatin analog in management of carcinoid syndrome
-
Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 1989;34 Suppl 3:14S-27.
-
(1989)
Dig Dis Sci
, vol.34
, Issue.3 SUPPL.
-
-
Vinik, A.1
Moattari, A.R.2
-
4
-
-
70350442637
-
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients wit metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group
-
Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients wit metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4656-4663
-
-
Rinke, A.1
Muller, H.-H.2
Schade-Brittinger, C.3
-
6
-
-
0034742565
-
90 Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
-
DOI 10.1023/A:1011160913619
-
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5. (Pubitemid 32725766)
-
(2001)
Annals of Oncology
, vol.12
, Issue.7
, pp. 941-945
-
-
Waldherr, C.1
Pless, M.2
Maecke, H.R.3
Haldemann, A.4
Mueller-Brand, J.5
-
7
-
-
0036976703
-
90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies
-
Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393-8.
-
(2002)
Biopolymers
, vol.66
, pp. 393-398
-
-
Paganelli, G.1
Bodei, L.2
Junak, D.H.3
Rocca, P.4
Papi, S.5
Sierra, M.L.6
-
8
-
-
0032725922
-
Yttrium-90 DOTATOC: First clinical results
-
DOI 10.1007/s002590050476
-
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47. (Pubitemid 29515605)
-
(1999)
European Journal of Nuclear Medicine
, vol.26
, Issue.11
, pp. 1439-1447
-
-
Otte, A.1
Herrmann, R.2
Heppeler, A.3
Behe, M.4
Jermann, E.5
Powell, P.6
Maecke, H.R.7
Muller, J.8
-
9
-
-
0036250672
-
90 Y-DOTATOC
-
Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC. J Nucl Med 2002;43:610-6. (Pubitemid 34507110)
-
(2002)
Journal of Nuclear Medicine
, vol.43
, Issue.5
, pp. 610-616
-
-
Waldherr, C.1
Pless, M.2
Maecke, H.R.3
Schumacher, T.4
Crazzolara, A.5
Nitzsche, E.U.6
Haldemann, A.7
Mueller-Brand, J.8
-
10
-
-
0036231005
-
90 Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial
-
Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In-and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55. (Pubitemid 34311081)
-
(2002)
Seminars in Nuclear Medicine
, vol.32
, Issue.2
, pp. 148-155
-
-
Virgolini, I.1
Britton, K.2
Buscombe, J.3
Moncayo, R.4
Paganelli, G.5
Riva, P.6
-
11
-
-
10744223113
-
3 ]octreotate
-
Kwekkeboom D, Bakker W, Kam BLR, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA (0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22. (Pubitemid 36692868)
-
(2003)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.30
, Issue.3
, pp. 417-422
-
-
Kwekkeboom, D.J.1
Bakker, W.H.2
Kam, B.L.3
Teunissen, J.J.M.4
Kooij, P.P.M.5
Herder, W.W.6
Feelders, R.A.7
Eijck, C.H.J.8
Jong, M.9
Srinivasan, A.10
Erion, J.L.11
Krenning, E.P.12
-
12
-
-
0037855590
-
Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labeled analogs only
-
de Jong M, Bernard HF, Breeman WA, et al. Combination of 90Y-and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y-or 177Lu-labeled analogs only. J Nucl Med 2002;43:123P-4.
-
(2002)
J Nucl Med
, vol.43
-
-
De Jong, M.1
Bernard, H.F.2
Breeman, W.A.3
-
13
-
-
14844350129
-
Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs
-
de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu-and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:13S-7.
-
(2005)
J Nucl Med
, vol.46
, Issue.1 SUPPL.
-
-
De Jong, M.1
Breeman, W.A.2
Valkema, R.3
Bernard, B.F.4
Krenning, E.P.5
-
14
-
-
33747822854
-
99m Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years' experience
-
DOI 10.1007/s00259-006-0113-7
-
Hubalewska-Dydejczyk A, Fröss-Baron K, Mikolajczak R, Maecke HR, Huszno B, Pach D, et al. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 2006;33:1123-33. (Pubitemid 44488531)
-
(2006)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.33
, Issue.10
, pp. 1123-1133
-
-
Hubalewska-Dydejczyk, A.1
Fross-Baron, K.2
Mikolajczak, R.3
Maecke, H.R.4
Huszno, B.5
Pach, D.6
Sowa-Staszczak, A.7
Janota, B.8
Szybinski, P.9
Kulig, J.10
-
15
-
-
27744479810
-
0 ]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization?
-
Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0, Tyr3, Thr8]octreotide and [111In-DTPA0] octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561-9. (Pubitemid 46173268)
-
(2005)
Journal of Nuclear Medicine
, vol.46
, Issue.9
, pp. 1561-1569
-
-
Storch, D.1
Behe, M.2
Walter, M.A.3
Chen, J.4
Powell, P.5
Mikolajczak, R.6
Macke, H.R.7
-
16
-
-
0031911476
-
Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
-
DOI 10.1007/s002590050216
-
Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12. (Pubitemid 28130048)
-
(1998)
European Journal of Nuclear Medicine
, vol.25
, Issue.2
, pp. 201-212
-
-
Behr, T.M.1
Goldenberg, D.M.2
Becker, W.3
-
17
-
-
0037601663
-
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
-
DOI 10.1007/s00259-002-0982-3
-
Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15. (Pubitemid 36692887)
-
(2003)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.30
, Issue.1
, pp. 9-15
-
-
Rolleman, E.J.1
Valkema, R.2
De Jong, M.3
Kooij, P.P.M.4
Krenning, E.P.5
-
18
-
-
0037993795
-
3 - octreotide (SMT487) - A phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
-
Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA (0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510-8. (Pubitemid 36559829)
-
(2003)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.30
, Issue.4
, pp. 510-518
-
-
Jamar, F.1
Barone, R.2
Mathieu, I.3
Walrand, S.4
Labar, D.5
Carlier, P.6
De Camps, J.7
Schran, H.8
Chen, T.9
Smith, M.C.10
Bouterfa, H.11
Valkema, R.12
Krenning, E.P.13
Kvols, L.K.14
Pauwels, S.15
-
19
-
-
0034789262
-
Low-energy electron emitters for targeted radiotherapy of small tumours
-
DOI 10.1080/028418601750444141
-
Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602-8. (Pubitemid 32912438)
-
(2001)
Acta Oncologica
, vol.40
, Issue.5
, pp. 602-608
-
-
Bernhardt, P.1
Forssell-Aronsson, E.2
Jacobsson, L.3
Skarnemark, G.4
-
20
-
-
0028068643
-
Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung
-
Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med 1994;35(8):1381-9. (Pubitemid 24243156)
-
(1994)
Journal of Nuclear Medicine
, vol.35
, Issue.8
, pp. 1381-1389
-
-
Shen, S.1
DeNardo, G.L.2
Yuan, A.3
DeNardo, D.A.4
DeNardo, S.J.5
-
21
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
22
-
-
77956888457
-
Partial residuals for the proportional hazards regression model
-
Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
-
(1982)
Biometrika
, vol.69
, pp. 239-241
-
-
Schoenfeld, D.1
-
23
-
-
0035354343
-
3 ]octreotate for somatostatin receptor-targeted radionuclide therapy
-
DOI 10.1002/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L
-
de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA (0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-33. (Pubitemid 32385702)
-
(2001)
International Journal of Cancer
, vol.92
, Issue.5
, pp. 628-633
-
-
De Jong, M.1
Breeman, W.A.P.2
Bernard, B.F.3
Bakker, W.H.4
Schaar, M.5
Van Gameren, A.6
Bugaj, J.E.7
Erion, J.8
Schmidt, M.9
Srinivasan, A.10
Krenning, E.P.11
-
24
-
-
0242665495
-
90 Y: Peptide Receptor Radionuclide Therapy Results In Vitro
-
Capello A, Krenning EP, Breeman WA, Bernard BF, Konijnenberg MW, de Jong M. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 2003;18:761-8. (Pubitemid 37377311)
-
(2003)
Cancer Biotherapy and Radiopharmaceuticals
, vol.18
, Issue.5
, pp. 761-768
-
-
Capello, A.1
Krenning, E.P.2
Breeman, W.A.P.3
Bernard, B.F.4
Konijnenberg, M.W.5
De Jong, M.6
-
25
-
-
14844340284
-
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs
-
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:62S-6.
-
(2005)
J Nucl Med
, vol.46
, Issue.1 SUPPL.
-
-
Kwekkeboom, D.J.1
Mueller-Brand, J.2
Paganelli, G.3
Anthony, L.B.4
Pauwels, S.5
Kvols, L.K.6
-
26
-
-
43749091955
-
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival
-
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-30.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2124-2130
-
-
Kwekkeboom, D.J.1
De Herder, W.W.2
Kam, B.L.3
Van Eijck, C.H.4
Van Essen, M.5
Kooij, P.P.6
|